Originators that intentionally deceive the Israel Patent Office can be found liable under the law of ‘unjust enrichment’ to pay restitution to generics manufacturers that were “deterred from competing” with branded drugs based on the originator “injecting uncertainty” into the market and forcing generic sponsors to “manage their risks,” the top Israeli court has reaffirmed.
The compensatory precedent available to generics manufacturers is according to the majority decision of a panel of five Israeli Supreme...
